# Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Source: https://onco.cc/trials/nct03367572/  
OnCo record `nct03367572` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dexamethasone, Palonosetron and Netupitant and palonosetron in Breast cancer, run by University of Rochester NCORP Research Base, completed.

## Summary

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer is a phase 3 interventional study registered as NCT03367572 by University of Rochester NCORP Research Base, with 1363 participants recorded, started 2018-04-19 and reaching its primary completion in 2024-04-13. Interventions recorded: Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment. Conditions recorded: Breast Carcinoma.

Linked to the drug Netupitant and palonosetron because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03367572
- Phase: 3
- Setting: Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
- Sponsor: University of Rochester NCORP Research Base
- Enrolled: 1363

## Sources

- ClinicalTrials.gov NCT03367572: https://clinicaltrials.gov/study/NCT03367572

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Netupitant and palonosetron](https://onco.cc/drugs/netupitant-palonosetron/), [Palonosetron](https://onco.cc/drugs/palonosetron/)

---
JSON: https://onco.cc/api/v1/entities/nct03367572.json